secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001493152-24-033053
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Provectus converts $2.13M in director fees to Series D-1 Preferred shares
-------------------------------------------------------------------------

- Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.
- Preferred shares are convertible into 7,448,780 shares of common stock.
- Issuance covers fees owed through September 30, 2024; not under 2024 Equity Compensation Plan.
- Board approved on August 14, 2024; fees had been accruing since April 2017.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224033053/0001493152-24-033053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224033053/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer